Jpmorgan Chase & CO Edgewise Therapeutics, Inc. Put Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding EWTX
# of Institutions
145Shares Held
96.3MCall Options Held
45.7KPut Options Held
5.3K-
Orbimed Advisors LLC San Diego, CA15MShares$518 Million6.52% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.91MShares$307 Million2.42% of portfolio
-
Black Rock Inc. New York, NY6.02MShares$207 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY5.84MShares$201 Million1.4% of portfolio
-
Novo Holdings Hellerup, G75.55MShares$191 Million10.36% of portfolio
About Edgewise Therapeutics, Inc.
- Ticker EWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,171,700
- Market Cap $2.18B
- Description
- Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...